CymaBay Therapeutics, Inc.
(NASDAQ GS: CBAY)
Rigrodsky Law, P.A. is investigating CymaBay Therapeutics, Inc. (“CymaBay”) regarding possible breaches of fiduciary duties and other violations of law related to CymaBay’s agreement to be acquired by Gilead Sciences, Inc. Under the terms of the agreement, CymaBay shareholders will receive $ 32.50 per share in cash.